Continuous infusion versus intermittent administration of meropenem in critically ill patients. A multicenter randomized double blind trial. - Bolus versus continuous infusion of meropenem.

OSPEDALE SAN RAFFAELE0 个研究点目标入组 600 人开始时间: 2020年11月4日最近更新: 2023年12月4日

适应症

试验速览

暂无简介。

•1. Are at least 18 years old
•2. Need a new antibiotic treatment, by clinical judgment, with meropenem
•3. Are admitted to ICU
•4. Have Sepsis or septic shock
•5. Are able to express informed consent or by him/her next of kin or as requested by Ethical Committee.
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 300
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range 300

•.1. Are able to express informed consent and denying it
•2. Are already receiving study drug or other carbapenem both as a bolus or continuous infusion
•3. Have a known allergy or intolerance to study drug
•4. Have a little chance of survival, as defined by a SAPS II score more than 65 point
•5. Have concomitant acquired immunodeficiency syndrome (stage 3 according to CDC)
•6. Have received immunosuppressant or long-term corticosteroid therapy (more than 0.5 mg/kg/day for over 30 days)

发起方

OSPEDALE SAN RAFFAELE